Good at growing what? Peptide Baddies

Angiogenesis

An egg membrane, a rat hind limb with restricted blood flow, and human cells lining blood vessels: these were the settings for a BPC-157 study that found increased vessel density and VEGFR2 activity. VEGFR2 helps cells respond to a vessel-growth signal. Angiogenesis is the growth of new blood vessels, and in an injured tissue that is an appealing result.

I credit that experiment's precision: ‘repair’ becomes cells responding and vessels growing. Then comes the harder question. Tumours also depend on a blood supply. The possibility that pro-angiogenic peptides might encourage an unwanted process is a theoretical concern; human studies have not established that GLOW causes cancer or measured that risk. The BPC-157 review's cautious conclusion leaves the clinical question open.

‘Baddies’ is a tempting casting decision. Before handing out the costumes, I'd ask what the biology is doing. A mechanism can explain why something interests researchers and why its safety needs closer examination. Those two thoughts fit together.

Pigment and repair

GLOW combines GHK-Cu, BPC-157 and TB-500 under a name that promises a pleasing appearance. The underlying literature is much less tidy: GHK-Cu reviews discuss collagen and tissue remodelling, BPC-157 research includes the vessel-growth experiments above, and much of the evidence associated with TB-500 concerns its parent protein, thymosin beta-4. A review covering all three constituents describes promising animal findings alongside scarce rigorous human safety data. The combination itself has no controlled clinical trial.

Melanotan II takes the argument into pigmentation. Its small human tanning pilot produced measurable colour, while a separate erectile-function study showed how far the molecule's activity extends beyond skin. To me, a beauty-only category cannot accommodate that breadth of activity.

The GLOW page follows the repair story, including blue colour and third-party testing claims. The Melanotan II page follows pigment, appetite and the clinical reports of harm.

Safety questions

The sharpest difference between these subjects is the kind of uncertainty. Melanotan II has small direct human studies and serious case reports, including a renal infarction attributed by its authors to the compound. GLOW has constituent research and an untested combination. Neither offers a settled long-term safety profile, and neither is FDA-approved.

I'd distrust a ‘safer’ ranking built from those uneven records. An absence of blend trials leaves a blank space where a clinical safety estimate would have to go. The comparison lays out that difference; the questions page handles the recurring points about names, trials and half-life.